Whelan Financial Increases Holdings in Eli Lilly and Company (NYSE:LLY)

Whelan Financial increased its stake in Eli Lilly and Company (NYSE:LLY) by 13.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 456 shares of the company’s stock after acquiring an additional 55 shares during the period. Whelan Financial’s holdings in Eli Lilly and Company were worth $404,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the stock. Amarillo National Bank boosted its holdings in shares of Eli Lilly and Company by 268.6% in the 1st quarter. Amarillo National Bank now owns 5,459 shares of the company’s stock valued at $4,247,000 after buying an additional 3,978 shares in the last quarter. Tempus Wealth Planning LLC increased its position in shares of Eli Lilly and Company by 2.6% during the first quarter. Tempus Wealth Planning LLC now owns 2,288 shares of the company’s stock worth $1,780,000 after purchasing an additional 57 shares in the last quarter. Powers Advisory Group LLC increased its position in shares of Eli Lilly and Company by 2.6% during the first quarter. Powers Advisory Group LLC now owns 2,288 shares of the company’s stock worth $1,780,000 after purchasing an additional 58 shares in the last quarter. Park Edge Advisors LLC boosted its position in shares of Eli Lilly and Company by 70.6% in the 1st quarter. Park Edge Advisors LLC now owns 2,563 shares of the company’s stock valued at $1,994,000 after purchasing an additional 1,061 shares during the period. Finally, New Century Financial Group LLC boosted its position in shares of Eli Lilly and Company by 64.7% in the 1st quarter. New Century Financial Group LLC now owns 1,986 shares of the company’s stock valued at $1,545,000 after purchasing an additional 780 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Barclays reduced their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Finally, Bank of America lowered their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,009.00.

Eli Lilly and Company Trading Down 2.0 %

Shares of LLY opened at $829.84 on Friday. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock’s 50-day moving average is $913.71 and its two-hundred day moving average is $864.86. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market cap of $788.70 billion, a PE ratio of 89.71, a P/E/G ratio of 3.07 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 73.73% and a net margin of 20.48%. The firm’s revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.10 EPS. Equities analysts forecast that Eli Lilly and Company will post 13.79 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.63%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.